Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001437749-25-010263
Filing Date
2025-03-31
Accepted
2025-03-31 17:09:20
Documents
19
Period of Report
2025-05-21

Document Format Files

Seq Description Document Type Size
1 FORM PRE 14A vxrt20250330_pre14a.htm   iXBRL PRE 14A 815146
6 capvnet.jpg GRAPHIC 45249
7 capvtsr.jpg GRAPHIC 45139
8 proxy_page1.jpg GRAPHIC 159975
9 proxy_page2.jpg GRAPHIC 124012
  Complete submission text file 0001437749-25-010263.txt   2375042

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vxrt-20241231.xsd EX-101.SCH 4474
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vxrt-20241231_def.xml EX-101.DEF 2423
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vxrt-20241231_lab.xml EX-101.LAB 3181
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vxrt-20241231_pre.xml EX-101.PRE 1685
21 EXTRACTED XBRL INSTANCE DOCUMENT vxrt20250330_pre14a_htm.xml XML 119365
Mailing Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 (650) 550-3500
Vaxart, Inc. (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-35285 | Film No.: 25794840
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)